MiRus announced new early feasibility study results supporting the use of its Siegel transcatheter aortic valve replacement ...

Transcatheter aortic valve implantation (TAVI) is now an established treatment option for elderly patients with severe ...

Traditional operative risk calculators, such as the European System for Cardiac Operative Risk Evaluation II (EuroSCORE II), ...

A true test of durability will take many more years, but if the valve holds up, it’s “potentially a game changer,” say ...

About this study The objective of ENVISION is to evaluate the safety and effectiveness of the Navitor Transcatheter Aortic Valve Implantation (TAVI) System for treating patients with symptomatic, ...

In EARLY TAVR, intervention improved outcomes over waiting in patients with class II or no indications for AVR consideration.

There is currently no way to stop calcification of the aortic valve. If all else fails, the valve must be replaced. To better ...

Conclusion & Future Perspective As the population ages and the average lifespan increases, AV disease will become increasingly prevalent, particularly in older adults. With recent advancements in ...

Transcatheter aortic valve replacement has emerged as a valuable alternative to surgical aortic valve replacement in patients with severe aortic stenosis. Given the expansion of transcatheter aortic ...

In the setting of aortic or mitral valve disease, left‐sided pressure overload is transmitted across the pulmonary vasculature, with pulmonary hypertension being independently associated with worse ...

Objective To determine whether echocardiography-derived left ventricular filling pressure influences survival in patients with severe aortic stenosis (AS) undergoing aortic valve replacement (AVR).

Aortyx announced today that it brought in $16 million (€13.8 million) to support its bioresorbable aortic patch technology. The company expects the funding to help bring the patch to first-in ...